Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cochlear ( (AU:COH) ) has shared an update.
The Bank of New York Mellon Corporation and its related group entities have notified Cochlear Ltd that they have ceased to be substantial shareholders in the company as of 2 April 2026. This reduction in BNY Mellon’s holding may slightly alter Cochlear’s institutional shareholder mix, but the notice does not disclose transaction terms or indicate any immediate impact on the company’s operations or strategic direction.
BNY Mellon’s group entities are identified as associates under Australian corporations law due to being directly or indirectly owned and controlled by BNY Mellon. The change underscores routine portfolio adjustments by a major global custodian and asset manager, and Cochlear’s share register is likely to see a rebalancing among other institutional or retail investors rather than any direct governance change linked to BNY Mellon.
The most recent analyst rating on (AU:COH) stock is a Hold with a A$172.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
More about Cochlear
Cochlear Ltd is a medical device company specialising in implantable hearing solutions, including cochlear implants and related technologies. It operates in the global hearing health market, serving patients with moderate to profound hearing loss and supplying its products and services to healthcare providers and clinics worldwide.
YTD Price Performance: -33.04%
Average Trading Volume: 221,424
Technical Sentiment Signal: Sell
Current Market Cap: A$11.27B
See more insights into COH stock on TipRanks’ Stock Analysis page.